Orasis Pharmaceuticals
Latest round
- Series D
Last raised
- Oct 2024
Total raised
- $111M
Investors
- 9
About Orasis Pharmaceuticals
Orasis Pharmaceuticals Ltd, based in Israel, develops innovative ophthalmic solutions to enhance vision.Founded in 2015, Orasis Pharmaceuticals Ltd focuses on developing ophthalmic treatments to enhance visual capabilities. The company does not have any reported pivots in business strategy or known subsidiaries. Based in Herzliya, Israel, its founder has not been disclosed.Orasis Pharmaceuticals specializes in developing innovative ophthalmic solutions aimed at addressing presbyopia, a common age-related vision condition. Their flagship product, Qlosi™, is designed to combat the gradual loss of the eye's ability to focus on near objects due to aging. Qlosi™ functions by improving near visual acuity, allowing users to comfortably engage in everyday tasks such as reading and using digital devices without the need for cumbersome glasses or invasive procedures. The product is currently available in the United States through prescription services, including BlinkRx and Medvantx, and serves a substantial customer base of eye care professionals and patients grappling with the challenges of presbyopia.S.Orasis Pharmaceuticals generates revenue through the sale of its prescription product, Qlosi™, to eye care professionals who then provide it to their patients. The transaction structure operates primarily on a B2B basis, whereby the company partners with pharmacies and retail distributors like BlinkRx and Medvantx to facilitate access to its product. As a prescription-based offering, revenue is derived from transactions where healthcare providers prescribe Qlosi™ to patients, who subsequently purchase it through licensed pharmacies.4% for treating presbyopia in adults. The company aims to expand into new markets, seeking to enhance distribution and accessibility of Qlosi™ to a wider customer base.
Who invested in Orasis Pharmaceuticals
9 investors across 3 rounds
See all investors in Orasis Pharmaceuticals
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Orasis Pharmaceuticals
Who invested in Orasis Pharmaceuticals?
Orasis Pharmaceuticals has 9 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Orasis Pharmaceuticals raised?
Orasis Pharmaceuticals has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Orasis Pharmaceuticals last raise money?
Orasis Pharmaceuticals's most recent round on record is a Series D, in Oct 2024.
What does Orasis Pharmaceuticals do?
Orasis Pharmaceuticals Ltd, based in Israel, develops innovative ophthalmic solutions to enhance vision.
Where is Orasis Pharmaceuticals headquartered?
Orasis Pharmaceuticals is headquartered in Herzliya, Israel.
Which VCs invest in companies like Orasis Pharmaceuticals?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back pharmaceuticals companies at Orasis Pharmaceuticals's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series D
Raising like Orasis Pharmaceuticals? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.